Clinical trial
A Phase 2, Multicenter, Randomized, Open-Label, Active Control Study of REGN7508, a Factor XI Monoclonal Antibody, for Prevention of Venous Thromboembolism After Elective, Unilateral, Total Knee Arthroplasty (ROXI-VTE II)
NCT06454630 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Randomized, Open-Label, Active Control Study of REGN7508, a Factor XI Monoclonal Antibody, for Prevention of Venous Thromboembolism After Elective, Unilateral, Total Knee Arthroplasty (ROXI-VTE II)
- Lead sponsor
- Regeneron Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 27, 2024
- Completion date
- January 21, 2025
- Enrollment
- 179 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.